论文部分内容阅读
目的:探讨自体CIK细胞联合放化疗治疗中晚期子宫颈癌的临床疗效。方法:2010年10月至2015年7月开封市中心医院肿瘤诊疗中心住院的89例中晚期子宫颈癌患者,按照随机对照法以1∶1分为治疗组(44例,CIK细胞联合放化疗)和对照组(45例,单纯放化疗),比较分析两组患者治疗的有效率、生存期、免疫功能及生活质量。结果:治疗组总有效率明显高于对照组(88.64%vs 68.89%,P<0.05)。治疗组1、2、3年生存率分别为93.18%、77.27%、47.73%,高于对照组的88.88%、68.89%、42.22%,但差异不显著(P>0.05)。与治疗前相比,治疗组治疗后外周血中CD3~+、CD4~+/CD8~+显著上升(P<0.05),对照组患者治疗后外周血中CD3~+、CD4~+/CD8~+显著下降(P<0.05)。治疗组治疗25 d(T25)和治疗前1 d(B1)比较仅情感一项有显著差异(t=2.0976,P<0.05),而对照组T25与B1比较在躯体、角色、社会、整体健康有显著差异(t=3.3463、3.4080、2.3402、3.3010,P<0.05或P<0.01);两组间T25时躯体、社会、整体健康比较有显著差异(t=2.8262、2.5797、1.9923,P<0.05或P<0.01)。结论:CIK细胞联合放化疗治疗中晚期子宫颈癌患者比单纯放化疗近期疗效好,能够明显提高患者免疫功能、改善生活质量,但尚未看到生存时间延长的获益。
Objective: To investigate the clinical efficacy of autologous CIK cells combined with chemoradiotherapy in the treatment of advanced cervical cancer. Methods: From October 2010 to July 2015, 89 patients with advanced cervical cancer who were hospitalized in Cancer Center of Kaifeng Central Hospital were divided into treatment group (44 cases, CIK cells combined with radiotherapy and chemotherapy ) And control group (45 cases, radiotherapy and chemotherapy alone). The efficacy, survival time, immune function and quality of life of the two groups were compared. Results: The total effective rate in the treatment group was significantly higher than that in the control group (88.64% vs 68.89%, P <0.05). The 1, 2, 3-year survival rates of the treatment group were 93.18%, 77.27% and 47.73%, respectively, which were 88.88%, 68.89% and 42.22% higher than those in the control group respectively, but the difference was not significant (P> 0.05). The levels of CD3 ~ + and CD4 ~ + / CD8 ~ + in the peripheral blood were significantly increased in the treatment group compared with that before treatment (P <0.05) + Significantly decreased (P <0.05). There was significant difference (P <0.05) between the treatment group 25 days (T25) and B1 day before treatment (T = 2.0976, P <0.05), while the control group T25 compared with B1 in the physical, social, There was significant difference (t = 3.3463,3.4080,2.3402,3.3010, P <0.05 or P <0.01); there was significant difference in somatic, social and overall health between two groups at T25 (t = 2.8262, 2.5797, Or P <0.01). Conclusions: CIK cells combined with chemoradiotherapy in the treatment of advanced cervical cancer patients have better curative effect than radiotherapy and chemotherapy alone. They can significantly improve patients’ immune function and improve their quality of life, but have not yet seen the benefits of prolonged survival.